Phio Pharmaceuticals Corp. (PHIO): Total Liabilities
$1.34M
As of 2025-12-31
$1.71M
As of 2026-06-30
-12.1%
3-year compound annual growth
-13.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.34M | +32.0% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $1.01M | -37.9% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $1.63M | -17.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $1.97M | -39.0% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $3.24M | +19.0% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $2.72M | +18.8% | 2022-03-22, Balance as of period end |
| 2019-12-31 | $2.29M | +31.4% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $1.74M | n/a | 2020-03-26, Balance as of period end |
| No annual figure between 2013-12-31 and 2018-12-31. | |||
| 2013-12-31 | $2.08M | +21.7% | 2014-03-28, Balance as of period end |
| 2012-12-31 | $1.71M | -25.2% | 2014-03-28, Balance as of period end |
| 2011-12-31 | $2.28M | n/a | 2013-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $1.34M | +32.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $4.23M | -8.4% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $7.76M | +13.9% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $7.12M | +24.5% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $45.68M | +6.5% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $4.67M | +424.1% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $7.27M | +11.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
Compare PHIO, EMMA, ANVS, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗